With UBS, it is my pleasure to welcome Oguzhan Atay, Co-Founder and Chief Executive Officer of BillionToOne. Thank you for being here. I appreciate you making the trip. BillionToOne brings a compelling scientific foundation to important clinical questions, from prenatal screening with Unity to cancer care with Northstar. Lots to talk about, lots of exciting things going on in the company. Today, what we are going to do is we are really going to explore the growth runway, adoption, and really the balance between investment in growth, investment in science, and profitability. In terms of just essentially the discussion arc for today, I want to spend some time on platform differentiation. I want to talk a little bit about the quarter. Then we will go product category by product category. We will go Unity, Northstar, and then we will wrap up with some financials. That is the roadmap.
Just to start off, high level, what unmet need inspired BillionToOne? What inspired you to advance the science, advance the technology, and where does the QCT backbone that supports precise quantification create the greatest clinical and economic advantage relative to other solutions that are out there?
Cell-free DNA is a truly remarkable biomarker. It is the microcosm of the entire body, but it is also a very rare entity biomarker. What we realized was that as a scientist, we were seeing how, and maybe for the first time, an academic idea can turn into a very impactful clinical outcome very quickly. I was at Stanford, and looking at the evolution of cell-free DNA field, seeing firsthand how an academic research can impact millions of lives, change standards of care. We started looking into what more cell-free DNA can be used for. We realized that the most common genetic disorders in the world are not trisomies, are not Down syndrome or aneuploidies. They are these single gene conditions, and in particular sickle cell disease and beta thalassemia.
We realized that to be able to detect sickle cell disease and beta thalassemia and other single gene conditions directly from a maternal blood sample, you have to get down to single molecule level sensitivity, and you need to remove all sorts of other noise. That is what QCT technology allows us to do. Of course, as soon as we built the technology, we knew how it would be transformative, not just for prenatal testing, but across the board for cell-free DNA testing. It can unlock tremendous clinical value, especially as the problems become more difficult. As we go from large chromosomal abnormalities to single gene conditions, and from late-stage cancers to early-stage cancers and even early detection, the problem is no longer the signal. The problem is the noise.
We see this from actually the different approaches that different companies take to these more difficult technical problems. If you are looking at something that is 0.01% of the total DNA or lower, it is no longer about trying to sequence more. It's no longer about trying to look at more and more locations, because you are not limited by the signal. You are limited by the noise that that process brings in. This is why, regardless of what approaches that the others are taking, if you look at the clinical results for tissue-free MRD or early detection, performances are very similar, and they are not enough. They are not at the levels that we want them to be for them to be truly standards of care.
This is where I think QCT, by being able to reduce the noise, allows us to tackle those clinical problems that no brute force, kind of let's sequence as much as possible approach can solve. In simpler problems, it allows us to have industry-leading low level of COGS. The advantage of QCT technology is when we are solving a problem that another methodology can solve, for instance, either directly or indirectly, the COGS of solving it in other ways is going to be substantially higher than what we can do it for. But as we go into more and more difficult problems, especially in cancer, it's not even just a COGS question. It becomes much more of a capability question.
Right. Differences in limit of detection, the resolution that you can look at things with. It's interesting, a different discussion earlier today, and again, I'm not a scientist, but I've looked at a lot of papers. I play one on T.V. No. When you look at a lot of the cell-free DNA approaches, you do start to see certain areas where some of the technologies that have been advanced, some of the more traditional approaches, if you can talk about it that way, given we're still at a pretty early stage in the industry. The biology does seem to lead you to sort of the same conclusions in terms of what the limit of what you can do is, toggling between sensitivity and specificity. What you're describing is an approach that obviously, because of how it treats noise, can basically do better than those approaches.
But it does seem like some of those approaches are hitting their ceiling. It doesn't sound like you feel like you're at a point where you're hitting the limit of what you can do with your approach, factoring in the biology. Is that fair?
That is fair. I mean, if you think about tumor-informed MRD as a category, why does anyone do tumor-informed MRD? The concept of tumor-informed MRD is that when you sequence the cell-free DNA, you see real mutations, but you see all sorts of PCR errors, amplification errors, sequencing errors. It becomes very difficult to differentiate what is real or what is not.
Right.
That is the sensitivity-specificity trade-off in tissue-free MRD and early detection, right? If you call them, your sensitivity increases, but your specificity decreases. This is why there are so many more tumor-informed approaches, because it solves the noise problem. If you sequence the tissue to begin with, now you know which mutations are real, so you can just look at those mutations in cell-free DNA. But of course, tumor-informed MRD has logistical challenges, other problems. Of course, you can't do tumor-informed early detection.
Right.
Right?
Right.
You need to do it in a tissue-free manner. This is where our technology, I think, is going to shine the most, because we don't even have to compete with the tumor-informed approaches.
One more high-level question, and this is really interesting. We have talked about, and we are going to go into more detail about your journey in reproductive health, your advancements in cancer. With this approach, logically, there are other areas you could participate. In the long term, again, you have a lot to work with what you have now, but the QCT, the approach lends itself well to other areas, presumably including screening. Is that something on your long-term roadmap?
Absolutely. I mean, if you think about tissue-free MRD and early detection, they are essentially equivalent problems.
Right.
In fact, there are others where, in backbone, the same assay is being used for tissue-free MRD and early detection, because the problem is the same. You do not know what the tumor is, and what you are trying to do, you are trying to detect infinitesimal level of tumor in blood and differentiate someone who has cancer from someone who does not have cancer.
The problem statement, technical problem statement, is exactly the same for tissue-free MRD and early detection. From that perspective, once you solve one of them, actually you have solved the other problem as well. This is why we are so excited about our Clear line, because it really has that potential for screening.
Okay. That is great. All right, we are going to come back to cancer in a few. I want to start on Unity, as we talk about the different businesses. This is, for those who do not know, your blood-based prenatal screening portfolio. It includes single gene Fetal Risk Screen, and it anchors really the core, the major generator of revenue today. You grew, it was over 40% in the third quarter, so momentum continues to be strong. Building off of what we have already talked about, beyond panel breadth, what differentiates Unity Confirm and Fetal Risk Screen, in terms of clinical evidence, reportable results, workflow, economics? How do you think about the differentiation, and what matters most to clinicians?
In terms of differentiation, it is all of them, right? In terms of the gross margin and the profitability of our prenatal business, it is completely unmatched, not just compared to other prenatal businesses, but in molecular diagnostics in general. It is the engine that allows us to invest so heavily into our growth, into our clinical studies, into our oncology, while staying profitable. From a clinician perspective, this is not what drives the value for them. There, I think workflow has been a really critical differentiation for us, because our single gene NIPT is really the only single gene NIPT that is designed for general population use, that intended use, where partner testing does not have to be done.
That it makes that workflow so much easier for all these physicians, but also there are unique components of this that serves different parts of the different stakeholders in the clinician journey. If you think about our Fetal Antigen NIPT, which is only about 0.5% of patients, but those are the highest risk patients where it can truly save lives. If you think about from the perspective of a maternal-fetal medicine specialist, they see more alloimmunized patients in that category than the high-risk patients for aneuploidies that they get referred to. For them, it's a game changer.
Right? For them, it is more important than aneuploidy testing.
Right.
We get these very strong advocates due to different parts of the portfolio workflow that allow us to really bring in these accounts, because the maternal-fetal medicine specialist who is getting referred patients is advocating for the test. All these love the workflow of being able to have one test that cover not just all of their needs, but the needs after the patient is referred.
When you get that advocate on board, they presumably move everything over to you, right? You argue and demonstrate an advantage in a certain area. For the most part, that's going to lead to full capture of share in that account. Is that a reasonable way to think about it?
It usually is. Maternal-fetal medicine specialists are so specialized that they might still rely on other tests for certain other indications, but you become the test that they tell their OB-GYNs who are referring their high-risk patients to them to use us frontline. This is why I think the expansion of Unity Fetal Risk Screen was so important, because we had OB-GYNs who absolutely love the portfolio, the products that we offer, right? The workflow, covering ACOG-recommended conditions, the ease of use, and then the MFMs with the Fetal Antigen NIPT, Unity Confirm, game-changing products for them. But we didn't have something that completed that portfolio with larger panels, because we didn't even have a large carrier screening panel, let alone Fetal Risk Screen with the cell-free DNA for the baby. We weren't even testing the mother and the father in the traditional sense with large panels.
Right.
While this is not something that most OB-GYNs would typically use in their practice, this is something that genetic counselors absolutely need because they take care of the rare conditions. When you are going into health system, which is a lot of the remaining value, remaining opportunity is in the health systems for us. We had a lot of the support from OB-GYNs and MFMs, and not always from genetic counselors when we didn't have these larger panels. I think having now the full portfolio of products really make a big difference in advancing those conversations.
In terms of competitive response, Natera has expanded Fetal Focus. They can bundle offerings. How's Unity positioned as Natera and other more established providers essentially respond to what you've brought to market?
I think part of this is that we have so many other advantages in addition to single-gene NIPT that we continue to have a strong product advantage. The other part is that we are the ones with peer-reviewed publications. The last peer-reviewed publication, which is a prospective multi-site intended use population study, it was five years in the making. That makes a difference when two products are trying to be positioned in the same way.
The other discussion that we have with providers is about those competitive products and how they are designed. They are designed primarily to look at, for instance, linked locations across the genome, but they are not directly finding the causal variant. They are looking at the correlation. That can actually become a problem if the partner testing is not done. Even the tests that are designed are not actually designed to truly match the use cases that we can offer.
From a guideline standpoint, when we think about single-gene Fetal Risk Screen, there is still some evidence and access hurdles. How should we think about those?
In general, the coverage is not really there, but because this is a test that is done after the carrier testing, the fact that the insurance doesn't always cover it actually doesn't limit any of that.
You still want to do this test.
Yeah, you still want to do this test. It doesn't result in additional patient responsibilities or cost. This is because we have designed this so that it can be accessible to every patient, regardless of their insurance, regardless of their socioeconomic status. This is the beauty and the power of the QCT platform, that we can actually offer this this broadly.
While being a profitable company. Whereas, I think it's very difficult for others to do the same. That said, what we are really excited about in single-gene NIPT is that if PAMA is in place, right, on January 1, 2027, single-gene NIPT will get more than 100% increase in its Clinical Laboratory Fee Schedule. In the short term, without coverage, that might not mean a significant ASP lift.
But it's there.
But it is there.
Yeah.
In the long term, if there is coverage, that can result in 20% revenue increase overall for the company. That would become 20% profit margins as well.
So that's a good lead-in to my last Unity question. Keeping in mind, prenatal revenue rose 42% in the quarter. Your gross margins are quite robust. As you think about some of the things we just talked about, can you preserve the margin profile, and can the margin profile actually get better as mix evolves? Because there's some good guys and bad guys, but it does seem like, as you describe things and we think about the growth and where it's coming from, you might be able to preserve this margin, if not expand it.
Yeah, I think in prenatal, we can not only preserve this margin but expand it. We also are doing this fully with a long-term perspective. I think there is this potential misunderstanding that every test volume, every test is equal to each other.
Right.
That is absolutely not the case. I think, if you truly take a kind of founder long-term perspective to this, there are going to be even accounts that we walk away from. We don't see competitors doing that typically. Whereas we take a very long-term view, and when we are making an investment, let's say that we are opening up a phlebotomy service center to be able to access an account, we need to make sure that that has at least an ROI of 5: 1 or 10: 1. Whereas, others might actually do that at negative margin.
We don't make those decisions, and I think that really allows our prenatal to have both growth, but the profitability which we then can use for both growing our prenatal business and expanding our product portfolio and other things, but also invest in oncology and oncology's growth.
All right, so let's talk about Northstar. This is your blood-based oncology portfolio. Select is therapy selection, Response is treatment monitoring, and Clear is your move into MRD. This has been growing very robustly across the portfolio, obviously from different starting points. Let's start overall for Northstar, and we've talked about the differentiation of the overall platform. Here, you're selecting profile. Basically, you're looking at genomic alterations to inform therapy selection with Select. Response tracks treatment response through serial blood draws. What's different from the incumbents? Some of it is what we talked about in terms of the technology. Are there other attributes which you've been contemplating that are helping you win?
Of course. I think, from a clinician perspective, technology by itself doesn't matter—
Right.
as much. It is about what that means for the patient and their patient.
With respect to therapy selection, what we have been able to show with a head-to-head study against the incumbents, that we can detect 50% more actionable therapies. This is such a surprising number that sometimes physicians don't even believe us.
Right.
Right? They have been using these incumbents for years, and how can you come in and detect so many more actionable therapies? Are these real therapies? Will the patients respond to them? What we have been able to do is actually to offer research pilots in these clinics themselves so that they can see for themselves that we are truly better and that patients are responding to these tests. That, I think, not only creates a user, that creates an advocate. Really, our growth in oncology is all about access. Once you have access, and once you can do these pilots, once you can prove that you are so much better, you are going to get physicians to switch them because every patient who is sitting in front of them has cancer, they are dying.
Right.
They need better therapies. This is different from some of the prenatal discussions. In prenatal discussions, even if you have absolutely remarkable tests, and even if everything else is terrible, not that they are terrible, but even if they are, you are maybe helping one out of 100 patients, right, that has that condition.
Yeah, every patient who's ordering.
Yeah.
Wants it.
So it's like, in cancer, it is different.
Right.
Every patient needs the—
Right.
better test. From that perspective, oncologists are actually a lot more passionate about the tests that they do, especially if you can show that you are differentiated, that you can offer their patients something better. This is why I think, as we are getting into more and more of these clinics, actually our biggest drivers become referrals from the physicians who experience them. That opens up even more doors, and this is why we are seeing an acceleration of test volume growth.
That's true of both Select and Response?
Certainly. I think there are actually a lot of synergies—
Right.
between Select and Response, right? They kind of see how powerful the Response is, how we can detect the patient progressing even before scans. Then they might order another therapy selection test to see what might be driving that increase, change the therapy. So the combination actually becomes very powerful. Sometimes Response becomes a wedge to get into an account, but then, as they see that progression, they use a Select test, or it might be the Select test that gets you into account, but then Response allows you to get repeat testing.
Understood. Interesting. All right, let's talk about Clear and your positioning in MRD. This is a tissue-free MRD test. It's scheduled to launch in a few weeks, December 15th?
Yeah.
How do you think this is differentiated? I think I know what the answer is going to be, but we had an MRD panel yesterday, and one of the panelists, he was an evangelist for MRD. He loved it. He's been using it in his group, is using it in every cancer. They've been an early adopter. He made the point, listen, tumor-informed is always going to be better. There's logistical challenges, but it's always going to be better. It sounds like you believe this is positioned to close that gap, so maybe you can walk us through that.
Exactly. I think, today, if you speak with oncologists, right, they have to make this trade-off. There is the tumor-informed tests that are believed to be the kind of gold standard, more sensitive tests, but then the logistical challenges, dealing with the tissue, turnaround time, QC fail rates become really a big issue. They become bigger and bigger issue as you move away from colorectal cancer. The primary use case of MRD today is in colorectal.
Right.
Three, four, five years from now, other cancer types are probably going to be as big, if not bigger, in utilization.
Breast.
Exactly.
Yeah.
In those other cancer types, it becomes an issue to use tumor-informed tests. If you see failure rates are higher, the turnaround time becomes a problem. In some community oncology settings, they just logistically cannot deal with the tissue. What we are finding is that tumor-informed market, I think, is going to get very competitive and in some ways commoditized. But if you can have a tissue-free test where you don't have to sacrifice the sensitivity, it becomes a game changer.
Especially for community oncology settings where ease of use is so important as well. This is 80% of where the eventual MRD utilization is going to be. This is how we are positioning it. We are not saying we are the best tissue-free test. We are going beyond that. We are saying that you don't have to sacrifice the sensitivity. We have on par or better performance than some of these tumor-informed tests that you have been relying on for years now.
How do you get people to understand? I think the clinicians are going to understand the concept. How do you build? How do you get more buy-in that you're the solution to this problem?
I think head-to-head is critical. I think we can and we will need to generate, and we have been doing studies in the background across all these different cancer types that when we are saying that a patient is going to progress, that they are going to progress, we will need to be able to have great clinical outcomes and separation between the patients who are ctDNA positive and ctDNA negative. But that's not going to be enough by itself, right? Because no study is truly head-to-head.
Right.
So, even if we have great clinical outcomes, it is not going to convince the community, the oncologists, that this is as good as their tumor-informed test. This is where I think head-to-head comes in. If you can show in head-to-head studies that this is on par or better than tumor-informed tests, I think that becomes, especially for not everyone, but for majority of the providers, the evidence that you need. Of course, they are not going to trust you on day one. They are going to try you. They are going to use you along with some tumor-informed tests. They are going to see it for themselves.
And we have already done that on the Select side, though, right? As we kind of have these publications, show the—
Let us say you have not had You are not afraid of doing the head-to-head.
No, we are not afraid to do any head-to-head.
All right. That is the playbook.
Playbook.
Origin's a tissue of origin prediction add-on to Select. How important is that capability? Then going back to the question I asked about screening, I got to imagine there's some connection between this add-on and demonstrating your capabilities in different areas.
What we have found, initially, we thought that tissue of origin is not a huge problem.
Right.
We thought that, looking at the literature, only 3% of patients should have this issue where they have truly an unknown primary, which is causing the oncologist not know how to treat the patient, and they tend to have much worse outcomes compared to when they know what the tissue of origin is. What we have found, though, is that in community oncology settings, the number is actually higher, because all of the studies are typically coming from more academic oncology.
Top institutions.
Top institutions where they have so much access to additional tests, great pathology workups, where, yes, true tissue of unknown origin is 3%, but if you talk to community oncologists and see kind of uncertain diagnosis, it becomes closer to 10%-15%. And 10%-15% is large enough that if you ignore that population, it becomes difficult for them to use you as your primary test. This is why we found that tissue of origin is a very important add-on for those patients where this makes a really big difference. And we talked a lot about community oncology. What I want to clarify here also, we actually get a lot of academic oncologists as well as community oncologists that are using our tests, and both of them are very important.
But what we find is that when academic oncologists are using us, they are sending us their most difficult cases. Whereas when community oncologists are using us, if they believe that they are going to be helpful to their most difficult cases, they will use you for vast majority of their patients.
Yeah. Yeah, they're not. If anything, they want to do menu consolidation.
Yeah.
Right. A Q3 question. Oncology clinical testing revenue rose 96% to $17.1 million in the quarter. Have you disaggregated how much of that was Northstar Select versus Northstar Response? How much of it was new physician ads versus repeat testing? It's early, but have you spoken to any of those metrics?
I'm just going to do a quick math. We get about two Northstar Response tests to one Northstar Select test.
Okay.
But in terms of the revenue contribution, Northstar Select ASP is close to five times of the Northstar Response ASP.
Okay.
From that perspective, I would say that probably, you do the math, it's like 5:2 ratio.
In terms of where the revenue is.
In terms of where the revenue is.
Yeah.
But that also shows the great opportunity with Northstar Response.
Okay. 2027, I'm not going to, I mean, I'd love if you could, but that's not what I'm going to ask. How should, is there a framework we should think about in terms of how much growth we can get from prenatal versus oncology?
I think, in prenatal, if we ignore any kind of big events like guideline changes or other things that can be fully astronomical in terms of how much it would add, if we kind of ignore those things, if we ignore health systems, which is actually the bigger opportunity for us, as we look at potentially next year, but in the long term, even if you just look at the single specialty clinics and how much we can grow and how much we have been growing, then prenatal, with some of the ASP improvements that we have seen as well, the contribution can get to still about 20% growth on that business without any of those potential additions that would come. Then oncology, I think, test volumes are growing faster than 100% year-over-year, and we are seeing acceleration.
I think we will see similar growth in oncology, and that is not even taking into account Clear as well as some of the ASP lifts that we might have for Response. I think, as we get closer to the second half and end of 2027, actually more and more of the story is about oncology because the revenue contribution as well as the sequential growth will be very significantly oncology-oriented.
OPEX rose 56% in the third quarter. We should be thinking you're still very much in an operational investment phase well into next year, fair?
I think it is fair. I think one of the kind of important notes about that growth is also we have become public about a year ago. There are certainly some investments—
Fair. Yeah.
that we had to make for public company operations, accounting, finance, audits, all of those had to be significantly uplifted as part of the IPO. We are continuing to invest in also product launches, both across prenatal and oncology, as well as also oncology clinical studies. I think we will continue to invest, but we want to invest in a way that creates significant long-term value. Every investment that we make is not just ROI positive, but 5:1 , 10:1 ROI positive, so that long term, we are not just optimizing for growth, but we are optimizing for the combination of rapid growth and profitability.
You can hold on to the gross margin, which on the reproductive side was north of 70%, I think it was 71% in the quarter. Oncology's still 45%, but with more reimbursement, that gets better. So with volume, with gross margin improvement, and seeing some return on the growth investments you're making at the OPEX line, you can see over time how this gets better.
Yeah. I think prenatal is 75%, oncology is 45%, blended was 71%. I don't know whether we are—
Thank you.
We are always going to be at 71% because oncology is growing faster.
Right.
It is going to depend on prenatal's continued growth as well as the coverage decisions around Northstar Response and how fast MRD scales. The good thing about all of this is that we realize that even if the gross margin in the short term has one or two percentage point decreases, that is going to be really good news because that means that oncology is growing even faster than projected.
Right.
It's not going to impact the bottom line profitability because of the cost structure of our products. As opposed to many other MRD products here, MRD even by the end of first year should have around close to gross margin breakeven. This is not going to result in negative profitability.
Huge loss of burn. That's not happening. I know we're out of time. That being said, if we're sitting here a year from now, what do you think we're going to point to that was the biggest thing the investment community is missing on BillionToOne? Could be one year, could be three years.
I think in the long term, what is I don't know whether this is missing, but these are market both in the tissue-free MRD response monitoring and early detection, where having the combination of a tissue-free approach and the sensitivity is critical.
These are markets where it is going to take time. It's not going to be turning overnight. But over long term, I think the winners are going to be the companies that can grow rapidly, combine it with profitability, weather any of the volatility in the market so that they can continue to invest and have the best products, not necessarily the ones that are first to market.
All right. Let's leave it there. That's great. We really appreciate the time. Thank you.
Thank you.